Kohlmann R, Salmen A, Chan A, Knabbe C, Diekmann J, Brockmeyer N, Skaletz-Rorowski A, Michalik C, Gold R, Überla K (2015): Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Mult. Scler. 21 (14): 1823–1832.

Storcksdieck genannt Bonsmann M, Niezold T, Temchura V, Pissani F, Ehrhardt K, Brown EP, Osei-Owusu NY, Hannaman D, Hengel H, Ackerman ME, Streeck H, Nabi G, Tenbusch M, Überla K (2015): Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells.
J. Immunol. 195 (10): 4861–4872.

Tenbusch M, Ignatius R, Temchura V, Nabi G, Tippler B, Stewart-Jones G, Salazar AM, Sauermann Ü, Stahl-Hennig C, Überla K (2012): Risk of immunodeficiency virus infection may increase with vaccine-induced immune response.
J. Virol. 86 (19): 10533–10539.

Hamza IA, Jurzik L, Überla K, Wilhelm M (2011): Evaluation of pepper mild mottle virus, human picobirnavirus and Torque teno virus as indicators of fecal contamination in river water.
Water Res. 45 (3): 1358–1368.

Nchinda G, Amadu D, Trumpfheller C, Mizenina O, Überla K, Steinman RM (2010): Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells.
Proc. Natl. Acad. Sci. USA 107 (9): 4281–4286.

Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, Salazar AM, Überla K, Nieto K, Kleinschmidt J, Schulte R, Gissmann L, Müller M, Sacher A, Racz P, Steinman RM, Uguccioni M, Ignatius R (2009): Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.
PLoS Pathog. 5 (4): e1000373.

Nchinda G, Kuroiwa J, Oks M, Trumpfheller C, Park CG, Huang Y, Hannaman D, Schlesinger SJ, Mizenina O, Nussenzweig MC, Uberla K, Steinman RM (2008): The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.
J. Clin. Invest. 118 (4): 1427–1436.

Ternette N, Tippler B, Überla K, Grunwald T (2007): Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus.
Vaccine 25 (41): 7271–7279.

Stahl-Hennig C, Kuate S, Franz M, Suh YS, Stoiber H, Sauermann U, Tenner-Racz K, Norley S et al. (2007): Atraumatic oral spray immunization with replication-deficient viral vector vaccines.
J. Virol. 81 (23): 13180-13190. Epub Sep 26. mehr

van der Hoek L, Sure K, Ihorst G, Stang A, Pyrc K, Jebbink MF, Petersen G, Forster J, Berkhout B, Überla K (2005): Croup is associated with the novel coronavirus NL63.
PloS Med. 2 (8): e240.

Schnell T, Foley P, Wirth M, Münch J, Überla K (2000): Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus.
Hum. Gene Ther. 11 (3): 439–447.

Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, Überla K (1999): Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.
J. Clin. Virol. 13 (1–2): 71–80.

Überla K, Stahl-Hennig C, Böttiger D, Mätz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Öberg B, Sodroski J (1995): Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.
Proc. Natl. Acad. Sci. USA 92 (18): 8210-8214.